Development of Multifunctional Histone Deacetylase 6 Degraders with Potent Antimyeloma Activity

Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT Method

Livak, K. J., & Schmittgen, T. D. (2001) · Methods · doi:10.1006/meth.2001.1262 · Cited by 180,860 · see citing works

HDAC6 is a microtubule-associated deacetylase

Hubbert, C., Guardiola, A., Shao, R., Kawaguchi, Y., Ito, A., Nixon, A., Yoshida, M., Wang, X.-F., & Yao, T.-P. (2002) · Nature · doi:10.1038/417455a · Cited by 2,403 · see citing works

An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer

Soucy, T. A., Smith, P. G., Milhollen, M. A., Berger, A. J., Gavin, J. M., Adhikari, S., Brownell, J. E., Burke, K. E., Cardin, D. P., Critchley, S., et al. (2009) · Nature · doi:10.1038/nature07884 · Cited by 1,990 · see citing works

Lenalidomide Causes Selective Degradation of IKZF1 and IKZF3 in Multiple Myeloma Cells

Krönke, J., Udeshi, N. D., Narla, A., Grauman, P., Hurst, S. N., McConkey, M., Svinkina, T., Heckl, D., Comer, E., Li, X., et al. (2014) · Science · doi:10.1126/science.1244851 · Cited by 1,879 · see citing works

Phthalimide conjugation as a strategy for in vivo target protein degradation

Winter, G. E., Buckley, D. L., Paulk, J., Roberts, J. M., Souza, A., Dhe-Paganon, S., & Bradner, J. E. (2015) · Science · doi:10.1126/science.aab1433 · Cited by 1,760 · see citing works

Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors

Finnin, M. S., Donigian, J. R., Cohen, A., Richon, V. M., Rifkind, R. A., Marks, P. A., Breslow, R., & Pavletich, N. P. (1999) · Nature · doi:10.1038/43710 · Cited by 1,714 · see citing works

The Myeloma Drug Lenalidomide Promotes the Cereblon-Dependent Destruction of Ikaros Proteins

Lu, G., Middleton, R. E., Sun, H., Naniong, M., Ott, C. J., Mitsiades, C. S., Wong, K.-K., Bradner, J. E., & Kaelin, W. G. (2014) · Science · doi:10.1126/science.1244917 · Cited by 1,583 · see citing works

Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders

Falkenberg, K. J., & Johnstone, R. W. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4360 · Cited by 1,564 · see citing works

The Deacetylase HDAC6 Regulates Aggresome Formation and Cell Viability in Response to Misfolded Protein Stress

Kawaguchi, Y., Kovacs, J. J., McLaurin, A. C., Vance, J. M., Ito, A., & Yao, T. (2003) · Cell · doi:10.1016/s0092-8674(03)00939-5 · Cited by 1,529 · see citing works

Histone-deacetylase inhibitors: novel drugs for the treatment of cancer

Johnstone, R. W. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd772 · Cited by 1,515 · see citing works

Induced protein degradation: an emerging drug discovery paradigm

Lai, A. C., & Crews, C. M. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.211 · Cited by 1,486 · see citing works

Structural basis of PROTAC cooperative recognition for selective protein degradation

Gadd, M. S., Testa, A., Lucas, X., Chan, K.-H., Chen, W., Lamont, D. J., Zengerle, M., & Ciulli, A. (2017) · Nature Chemical Biology · doi:10.1038/nchembio.2329 · Cited by 1,242 · see citing works

Structure of the DDB1–CRBN E3 ubiquitin ligase in complex with thalidomide

Fischer, E. S., Böhm, K., Lydeard, J. R., Yang, H., Stadler, M. B., Cavadini, S., Nagel, J., Serluca, F., Acker, V., Lingaraju, G. M., et al. (2014) · Nature · doi:10.1038/nature13527 · Cited by 1,141 · see citing works

Hijacking the E3 Ubiquitin Ligase Cereblon to Efficiently Target BRD4

Lu, J., Qian, Y., Altieri, M., Dong, H., Wang, J., Raina, K., Hines, J., Winkler, J. D., Crew, A. P., Coleman, K., et al. (2015) · Chemistry & Biology · doi:10.1016/j.chembiol.2015.05.009 · Cited by 1,140 · see citing works

The dTAG system for immediate and target-specific protein degradation

Nabet, B., Roberts, J. M., Buckley, D. L., Paulk, J., Dastjerdi, S., Yang, A., Leggett, A. L., Erb, M. A., Lawlor, M. A., Souza, A., et al. (2018) · Nature Chemical Biology · doi:10.1038/s41589-018-0021-8 · Cited by 1,118 · see citing works

Lessons in PROTAC Design from Selective Degradation with a Promiscuous Warhead

Bondeson, D. P., Smith, B. E., Burslem, G. M., Buhimschi, A. D., Hines, J., Jaime-Figueroa, S., Wang, J., Hamman, B. D., Ishchenko, A., & Crews, C. M. (2018) · Cell Chemical Biology · doi:10.1016/j.chembiol.2017.09.010 · Cited by 923 · see citing works

Three proteins define a class of human histone deacetylases related to yeast Hda1p

Grozinger, C. M., Hassig, C. A., & Schreiber, S. L. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.9.4868 · Cited by 770 · see citing works

HDAC6 Modulates Cell Motility by Altering the Acetylation Level of Cortactin

Zhang, X. M., Yuan, Z., Zhang, Y., Yong, S., Salas-Burgos, A., Koomen, J. M., Olashaw, N., Parsons, J. T., Yang, X., Dent, S., et al. (2007) · Molecular Cell · doi:10.1016/j.molcel.2007.05.033 · Cited by 731 · see citing works

A novel cereblon modulator recruits GSPT1 to the CRL4CRBN ubiquitin ligase

Matyskiela, M. E., Lu, G., Ito, T., Pagarigan, B., Lu, C.-C., Miller, K., Fang, W., Wang, N.-Y., Nguyen, D., Houston, J., et al. (2016) · Nature · doi:10.1038/nature18611 · Cited by 701 · see citing works

The Advantages of Targeted Protein Degradation Over Inhibition: An RTK Case Study

Burslem, G. M., Smith, B. E., Lai, A. C., Jaime-Figueroa, S., McQuaid, D. C., Bondeson, D. P., Toure, M., Dong, H., Qian, Y., Wang, J., et al. (2018) · Cell Chemical Biology · doi:10.1016/j.chembiol.2017.09.009 · Cited by 686 · see citing works

Modular PROTAC design for the degradation of oncogenic BCR-ABL

Lai, A. C., Toure, M., Hellerschmied, D., Salami, J., Jaime‐Figueroa, S., Ko, E., Hines, J., & Crews, C. M. (2016) · Angewandte Chemie International Edition · doi:10.1002/anie.201507634 · Cited by 618 · see citing works

Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma

Santo, L., Hideshima, T., Kung, A. L., Tseng, J.-C., Tamang, D., Yang, M., Jarpe, M., van Duzer, J. H., Mazitschek, R., Ogier, W. C., et al. (2012) · Blood · doi:10.1182/blood-2011-10-387365 · Cited by 616 · see citing works

Plasticity in binding confers selectivity in ligand-induced protein degradation

Nowak, R. P., DeAngelo, S. L., Buckley, D., He, Z., Donovan, K. A., An, J., Safaee, N., Jedrychowski, M. P., Ponthier, C. M., Ishoey, M., et al. (2018) · Nature Chemical Biology · doi:10.1038/s41589-018-0055-y · Cited by 615 · see citing works

Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma

Hideshima, T., Bradner, J. E., Wong, J. Y. Y., Chauhan, D., Richardson, P. G. G., Schreiber, S. L., & Anderson, K. C. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0503221102 · Cited by 598 · see citing works

Structure of the human Cereblon-DDB1-lenalidomide complex reveals basis for responsiveness to thalidomide analogs

Chamberlain, P. P., Lopez-Girona, A., Miller, K., Carmel, G., Pagarigan, B., Chie-Leon, B., Rychak, E., Corral, L. G., Ren, Y. J., Wang, M., et al. (2014) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.2874 · Cited by 531 · see citing works

A Comprehensive Mathematical Model for Three-Body Binding Equilibria

Douglass, E. F., Miller, C. J., Sparer, G., Shapiro, H., & Spiegel, D. A. (2013) · Journal of the American Chemical Society · doi:10.1021/ja311795d · Cited by 472 · see citing works

Delineating the role of cooperativity in the design of potent PROTACs for BTK

Zorba, A., Nguyen, C., Xu, Y., Starr, J., Borzilleri, K., Smith, J., Zhu, H., Farley, K. A., Ding, W., Schiemer, J., et al. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1803662115 · Cited by 419 · see citing works

Histone deacetylases in acute myeloid leukaemia show a distinctive pattern of expression that changes selectively in response to deacetylase inhibitors

Bradbury, C. A., Khanim, F. L., Hayden, R., Bunce, C. M., White, D. A., Drayson, M. T., Craddock, C., & Turner, B. M. (2005) · Leukemia · doi:10.1038/sj.leu.2403910 · Cited by 403 · see citing works

HDAC6, at the crossroads between cytoskeleton and cell signaling by acetylation and ubiquitination

Boyault, C., Sadoul, K., Pabion, M., & Khochbin, S. (2007) · Oncogene · doi:10.1038/sj.onc.1210614 · Cited by 397 · see citing works

Discovery of a Small-Molecule Degrader of Bromodomain and Extra-Terminal (BET) Proteins with Picomolar Cellular Potencies and Capable of Achieving Tumor Regression

Zhou, B. N., Hu, J., Xu, F., Chen, Z., Bai, L., Fernández‐Salas, E., Lin, M., Liu, L., Yang, C., Zhao, Y., et al. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b01816 · Cited by 373 · see citing works

Expanding the diversity of chemical protein modification allows post-translational mimicry

van Kasteren, S. I., Kramer, H., Jensen, H. H., Campbell, S. J., Kirkpatrick, J. M., Oldham, N. J., Anthony, D. C., & Davis, B. G. (2007) · Nature · doi:10.1038/nature05757 · Cited by 316 · see citing works

Structural insights into HDAC6 tubulin deacetylation and its selective inhibition

Miyake, Y., Keusch, J. J., Wang, L., Saito, M., Hess, D., Wang, X., Melancon, B. J., Helquist, P., Gut, H., & Matthias, P. (2016) · Nature Chemical Biology · doi:10.1038/nchembio.2140 · Cited by 315 · see citing works

The Rise of Azide–Alkyne 1,3-Dipolar ‘Click’ Cycloaddition and its Application to Polymer Science and Surface Modification

Evans, R. A. (2007) · Australian Journal of Chemistry · doi:10.1071/ch06457 · Cited by 313 · see citing works

Discovery of MD-224 as a First-in-Class, Highly Potent, and Efficacious Proteolysis Targeting Chimera Murine Double Minute 2 Degrader Capable of Achieving Complete and Durable Tumor Regression

Li, Y., Yang, J., Aguilar, A., McEachern, D., Przybranowski, S., Liu, L., Yang, C.-Y., Wang, M., Han, X., & Wang, S. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00909 · Cited by 312 · see citing works

Discovery of QCA570 as an Exceptionally Potent and Efficacious Proteolysis Targeting Chimera (PROTAC) Degrader of the Bromodomain and Extra-Terminal (BET) Proteins Capable of Inducing Complete and Durable Tumor Regression

Qin, C., Hu, Y., Zhou, B., Fernandez-Salas, E., Yang, C.-Y., Liu, L., McEachern, D., Przybranowski, S., Wang, M., Stuckey, J., et al. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00506 · Cited by 281 · see citing works

Chemically Induced Degradation of Sirtuin 2 (Sirt2) by a Proteolysis Targeting Chimera (PROTAC) Based on Sirtuin Rearranging Ligands (SirReals)

Schiedel, M., Herp, D., Hammelmann, S., Swyter, S., Lehotzky, A., Robaa, D., Oláh, J., Ovádi, J., Sippl, W., & Jung, M. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b01872 · Cited by 275 · see citing works

Proteolysis-Targeting Chimeras: Induced Protein Degradation as a Therapeutic Strategy

Ottis, P., & Crews, C. M. (2017) · ACS Chemical Biology · doi:10.1021/acschembio.6b01068 · Cited by 227 · see citing works

Ricolinostat plus lenalidomide, and dexamethasone in relapsed or refractory multiple myeloma: a multicentre phase 1b trial

Yee, A. J., Bensinger, W., Supko, J. G., Voorhees, P. M., Berdeja, J. G., Richardson, P. G. G., Libby, E. N., Wallace, E. E., Birrer, N., Burke, J. N., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30375-8 · Cited by 205 · see citing works

Selective Histone Deacetylase 6 Inhibitors Bearing Substituted Urea Linkers Inhibit Melanoma Cell Growth

Bergman, J. A., Woan, K. V., Perez-Villarroel, P., Villagra, A., Sotomayor, E. M., & Kozikowski, A. P. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm301098e · Cited by 200 · see citing works

Development of the first small molecule histone deacetylase 6 (HDAC6) degraders

Yang, K., Song, Y., Xie, H., Wu, H., Wu, Y.-T., Leisten, E. D., & Tang, W. (2018) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2018.05.057 · Cited by 190 · see citing works

Modulating PCAF/GCN5 Immune Cell Function through a PROTAC Approach

Bassi, Z. I., Fillmore, M. C., Miah, A. H., Chapman, T. D., Maller, C., Roberts, E. J., Davis, L. C., Lewis, D. E., Galwey, N. W., Waddington, K. E., et al. (2018) · ACS Chemical Biology · doi:10.1021/acschembio.8b00705 · Cited by 186 · see citing works

Essential role of HDAC6 in the regulation of PD‐L1 in melanoma

Lienlaf, M., Perez-Villarroel, P., Knox, T. J., Pabon, M. M., Sahakian, E., Powers, J. J., Woan, K. V., Lee, C., Cheng, F., Deng, S., et al. (2016) · Molecular Oncology · doi:10.1016/j.molonc.2015.12.012 · Cited by 171 · see citing works

Small‐Molecule Control of Intracellular Protein Levels through Modulation of the Ubiquitin Proteasome System

Buckley, D. L., & Crews, C. M. (2014) · Angewandte Chemie International Edition · doi:10.1002/anie.201307761 · Cited by 153 · see citing works

Recent advances in the discovery of potent and selective HDAC6 inhibitors

Wang, X.-X., Wan, R.-Z., & Liu, Z.-P. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.10.040 · Cited by 152 · see citing works

Developing potent PROTACs tools for selective degradation of HDAC6 protein

An, Z., Lv, W., Su, S., Wu, W., & Rao, Y. (2019) · Protein & Cell · doi:10.1007/s13238-018-0602-z · Cited by 133 · see citing works

Development and Therapeutic Implications of Selective Histone Deacetylase 6 Inhibitors

Kalin, J. H., & Bergman, J. A. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm4001659 · Cited by 129 · see citing works

Boiling water-catalyzed neutral and selective N-Boc deprotection

(2009) · doi:10.1039/b910239f · Cited by 121 · see citing works

Ubiquitin Proteasome System Stress Underlies Synergistic Killing of Ovarian Cancer Cells by Bortezomib and a Novel HDAC6 Inhibitor

Bazzaro, M., Lin, Z., Santillan, A., Lee, M. K., Wang, M., Chan, K. C. G., Bristow, R. E., Mazitschek, R., Bradner, J. E., & Roden, R. B. S. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0642 · Cited by 119 · see citing works

Synthesis and Biological Investigation of Phenothiazine-Based Benzhydroxamic Acids as Selective Histone Deacetylase 6 Inhibitors

Vögerl, K., Ong, N., Senger, J., Herp, D., Schmidtkunz, K., Marek, M., Müller, M., Bartel, K., Shaik, T. B., Porter, N. J., et al. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b01090 · Cited by 104 · see citing works

Discovery of histone deacetylase 8 selective inhibitors

Tang, W., Luo, T., Greenberg, E. F., Bradner, J. E., & Schreiber, S. L. (2011) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2011.01.134 · Cited by 95 · see citing works

(N-Hydroxycarbonylbenylamino)quinolines as Selective Histone Deacetylase 6 Inhibitors Suppress Growth of Multiple Myeloma in Vitro and in Vivo

Lee, H., Nepali, K., Huang, F.-I., Chang, C. S., Lai, M.-J., Li, Y.-H., Huang, H.-L., Yang, C., & Liou, J. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b01404 · Cited by 89 · see citing works

Design and synthesis of estrogen receptor degradation inducer based on a protein knockdown strategy

Demizu, Y., Okuhira, K., Motoi, H., Ohno, A., Shoda, T., Fukuhara, K., Okuda, H., Naito, M., & Kurihara, M. (2011) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2011.11.086 · Cited by 88 · see citing works

High-selective HDAC6 inhibitor promotes HDAC6 degradation following autophagy modulation and enhanced antitumor immunity in glioblastoma

Liu, J.-R., Yu, C., Hung, P.-Y., Hsin, L., & Chern, J. (2019) · Biochemical Pharmacology · doi:10.1016/j.bcp.2019.03.023 · Cited by 83 · see citing works

Marbostat-100 Defines a New Class of Potent and Selective Antiinflammatory and Antirheumatic Histone Deacetylase 6 Inhibitors

Sellmer, A., Stangl, H., Beyer, M., Grünstein, E., Leonhardt, M., Pongratz, H., Eichhorn, E., Elz, S., Striegl, B., Jenei‐Lanzl, Z., et al. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b01593 · Cited by 80 · see citing works

Overexpression of histone deacetylase 6 contributes to accelerated migration and invasion activity of hepatocellular carcinoma cells

Kanno, K., Kanno, S., Nitta, H., Uesugi, N., Sugai, T., Masuda, T., Wakabayashi, G., & Maesawa, C. (2012) · Oncology Reports · doi:10.3892/or.2012.1898 · Cited by 76 · see citing works

Combination of a novel HDAC6 inhibitor ACY-241 and anti-PD-L1 antibody enhances anti-tumor immunity and cytotoxicity in multiple myeloma

Ray, A., Das, D. S., Song, Y. Y., Hideshima, T., Tai, Y., Chauhan, D., & Anderson, K. C. (2017) · Leukemia · doi:10.1038/leu.2017.322 · Cited by 76 · see citing works

5-Aroylindoles Act as Selective Histone Deacetylase 6 Inhibitors Ameliorating Alzheimer’s Disease Phenotypes

Lee, H., Fan, S.-J., Huang, F.-I., Chao, H.-Y., Hsu, K., Lin, T. E., Yeh, T., Lai, M.-J., Li, Y.-H., Huang, H.-L., et al. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00151 · Cited by 76 · see citing works

Identification and Structure–Activity Relationship of HDAC6 Zinc-Finger Ubiquitin Binding Domain Inhibitors

de Freitas, R. F., Harding, R., Franzoni, I., Ravichandran, M., Mann, M. K., Ouyang, H., Lautens, M., Santhakumar, V., Arrowsmith, C. H., & Schapira, M. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00258 · Cited by 69 · see citing works

Rational combination treatment with histone deacetylase inhibitors and immunomodulatory drugs in multiple myeloma

Hideshima, T., Cottini, F., Ohguchi, H., Jakubı́ková, J., Görgün, G., Mimura, N., Tai, Y., Munshi, N. C., Richardson, P. G. G., & Anderson, K. C. (2015) · Blood Cancer Journal · doi:10.1038/bcj.2015.38 · Cited by 65 · see citing works

Histone deacetylase inhibitors in multiple myeloma: from bench to bedside

Harada, T., Hideshima, T., & Anderson, K. C. (2016) · International Journal of Hematology · doi:10.1007/s12185-016-2008-0 · Cited by 60 · see citing works

IIp45 Inhibits Cell Migration through Inhibition of HDAC6

Wu, Y., Song, S. W., Sun, J., Bruner, J. M., Fuller, G. N., & Zhang, W. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.063354 · Cited by 56 · see citing works

Quinazolin-2,4-dione-Based Hydroxamic Acids as Selective Histone Deacetylase-6 Inhibitors for Treatment of Non-Small Cell Lung Cancer

Yu, C., Hung, P.-Y., Yang, H.-T., et al. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b01590 · Cited by 54 · see citing works

Role of the HDAC6/STAT3 pathway in regulating PD-L1 expression in osteosarcoma cell lines

Keremu, A., Aimaiti, A., Liang, Z., & Zou, X. (2018) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-018-3721-6 · Cited by 53 · see citing works

Tumor-Suppressor Role of Notch3 in Medullary Thyroid Carcinoma Revealed by Genetic and Pharmacological Induction

Jaskula‐Sztul, R., Eide, J. G., Tesfazghi, S., Dammalapati, A., Harrison, A. D., Yu, X.-M., Scheinebeck, C. M., Winston‐McPherson, G. N., Kupcho, K. R., Robers, M. B., et al. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-0073 · Cited by 40 · see citing works

Mechanisms of Resistance in Multiple Myeloma

Papadas, A., & Asimakopoulos, F. A. (2017) · Handbook of experimental pharmacology · doi:10.1007/164_2017_10 · Cited by 26 · see citing works

Novel analogs targeting histone deacetylase suppress aggressive thyroid cancer cell growth and induce re-differentiation

Jang, S., Yu, X.-M., Odorico, S. K., Clark, M., Jaskula‐Sztul, R., Schienebeck, C. M., Kupcho, K. R., Harrison, A. D., Winston‐McPherson, G. N., Tang, W., et al. (2015) · Cancer Gene Therapy · doi:10.1038/cgt.2015.37 · Cited by 24 · see citing works

Selective HDAC6 Inhibitor ACY-241, an Oral Tablet, Combined with Pomalidomide and Dexamethasone: Safety and Efficacy of Escalation and Expansion Cohorts in Patients with Relapsed or Relapsed-and-Refractory Multiple Myeloma (ACE-MM-200 Study)

Niesvizky, R., Richardson, P. G. G., Yee, A. J., et al. (2016) · Blood · doi:10.1182/blood.v128.22.3307.3307 · Cited by 21 · see citing works

Intracellular insulin quantification by cell-ELISA

Andersen, P. L., & Vermette, P. (2016) · Experimental Cell Research · doi:10.1016/j.yexcr.2016.06.014 · Cited by 14 · see citing works

Mapping the Degradable Kinome Provides a Resource for Expedited Degrader Development

Donovan, K. A., Ferguson, F. M., Bushman, J. W., Eleuteri, N. A., Bhunia, D., Ryu, S., Tan, L., Shi, K., Yue, H., Liu, X., et al. (2020) · Cell · doi:10.1016/j.cell.2020.10.038 · Cited by 359 · see citing works

Degradation of proteins by PROTACs and other strategies

Wang, Y., Jiang, X., Feng, F., Liu, W., & Sun, H. (2020) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2019.08.001 · Cited by 335 · see citing works

Proteolysis‐targeting chimeras in drug development: A safety perspective

Moreau, K., Coen, M., Zhang, A. X., Pachl, F., Castaldi, M. P., Dahl, G., Boyd, H., Scott, C., & Newham, P. (2020) · British Journal of Pharmacology · doi:10.1111/bph.15014 · Cited by 229 · see citing works

Targeting histone deacetylases for cancer therapy: Trends and challenges

Liang, T., Wang, F., Elhassan, R. M., Cheng, Y., Tang, X., Chen, W., Fang, H., & Hou, X. (2023) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2023.02.007 · Cited by 222 · see citing works

Proteolysis targeting chimeras (PROTACs) are emerging therapeutics for hematologic malignancies

He, Y., Khan, S., Huo, Z., Lv, D., Zhang, X., Liu, X., Yuan, Y., Hromas, R., Xu, M., Zheng, G., et al. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00924-z · Cited by 126 · see citing works

PROTAC-mediated degradation of class I histone deacetylase enzymes in corepressor complexes

Smalley, J. P., Adams, G. E., Millard, C. J., Song, Y., Norris, J. K. S., Schwabe, J. W. R., Cowley, S. M., & Hodgkinson, J. T. (2020) · Chemical Communications · doi:10.1039/d0cc01485k · Cited by 121 · see citing works

Development of Selective Histone Deacetylase 6 (HDAC6) Degraders Recruiting Von Hippel–Lindau (VHL) E3 Ubiquitin Ligase

Yang, K., Wu, H., Zhang, Z., Leisten, E. D., Nie, X., Liu, B., Wen, Z., Zhang, J., Cunningham, M. D., & Tang, W. (2020) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.0c00046 · Cited by 124 · see citing works

Plasticity in designing PROTACs for selective and potent degradation of HDAC6

Yang, H., Lv, W., He, M., Deng, H., Li, H., Wu, W., & Rao, Y. (2019) · Chemical Communications · doi:10.1039/c9cc08509b · Cited by 108 · see citing works

Medicinal chemistry updates of novel HDACs inhibitors (2020 to present)

He, X., Hui, Z., Xu, L., Bai, R., Gao, Y., Wang, Z., Xie, T., & Ye, X.-Y. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113946 · Cited by 89 · see citing works

Discovery of thalidomide-based PROTAC small molecules as the highly efficient SHP2 degraders

Yang, X., Wang, Z., Pei, Y., Song, N., Xu, L., Feng, B., Wang, H., Luo, X., Hu, X., Qiu, X., et al. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113341 · Cited by 85 · see citing works

Discovery of a Novel BCL-X_L PROTAC Degrader with Enhanced BCL-2 Inhibition

Pal, P., Thummuri, D., Lv, D., Liu, X., Zhang, P., Hu, W., Poddar, S. K., Hua, N., Khan, S., Yuan, Y., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00517 · Cited by 60 · see citing works

Potent and Selective Mitogen-Activated Protein Kinase Kinase 1/2 (MEK1/2) Heterobifunctional Small-molecule Degraders

Hu, J., Wei, J., Yim, H., Wang, L., Xie, L., Jin, M. S., Kabir, M., Qin, L., Chen, X., Liu, J., et al. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01609 · Cited by 43 · see citing works

Discovery of the First Histone Deacetylase 6/8 Dual Inhibitors

Olson, D. E., Wagner, F. F., Kaya, T., Gale, J. P., Aidoud, N., Davoine, E. L., Lazzaro, F., Weïwer, M., Zhang, Y., & Holson, E. B. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm400390r · Cited by 94 · see citing works

The structural requirements of histone deacetylase inhibitors: C4-modified SAHA analogs display dual HDAC6/HDAC8 selectivity

Negmeldin, A. T., Knoff, J. R., & Pflum, M. K. H. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.10.076 · Cited by 51 · see citing works

Histone deacetylase (HDAC); HDAC1; HDAC2; HDAC6; HDAC8

(2009) · Science-Business eXchange · doi:10.1038/scibx.2009.695

Inhibitors of Human Histone Deacetylase: Synthesis and Enzyme Assay of Hydroxamates with Piperazine Linker

Chakrabarty, S., Jasmine, J., Bhadaliya, C., Sinha, B. N., Mahesh, A., Bai, H., Blond, S. Y., & Jayaprakash, V. (2010) · Archiv der Pharmazie · doi:10.1002/ardp.200900117 · Cited by 7 · see citing works

Design, and synthesis of N‐benzyl spiro‐piperidine hydroxamic acid‐based derivatives: Histone deacetylase inhibitory activity and drug‐likeness prediction

Kurapati, C., Paidikondala, K., Badavath, V. N., Parveen, S., Singh, O. V., & Gundla, R. (2022) · Journal of Heterocyclic Chemistry · doi:10.1002/jhet.4538 · Cited by 4 · see citing works